Please login to the form below

Not currently logged in
Email:
Password:

Avillion names Allison Jeynes-Ellis CEO

Her career to date includes experience at ABPI, J&J, Roche, Wyeth, BMS and Novartis

Avillion, Allison Jeynes EllisAvillion has appointed the well-travelled and experienced Dr Allison Jeynes-Ellis as the company's new CEO.

Jeynes-Ellis has spent time at several major pharma companies in her 22-year career in the industry, including senior roles at Roche, Genentech Wyeth (now Pfizer), Bristol-Myers Squibb, Novartis, Nycomed and trade body the Association of the British Pharmaceutical Industry (ABPI).

These includes medical director positions and specific oncology positions and she also has consultancy experience at Johnson & Johnson and AstraZeneca.

Most recently Jeynes-Ellis was chief medical officer at Avillion, a UK-based company she co-founded in 2011 to focus on the co-development and financing of late-stage drug candidates.

She will now lead Avillion as it prepares to advance its first collaborative development agreement with Pfizer to conduct a global phase III clinical trial evaluating Bosulif (bosutinib) as a first-line treatment in chronic myelogenous leukaemia.

Kurt Wheeler, a non-executive director of Avillion, said: “We are confident that, under Allison's leadership, this agreement will be the first of several that Avillion signs over the coming years.”

19th February 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics